Theriva Biologics Provides Response to Unusual Market Action
Rhea-AI Summary
Theriva Biologics (NYSE American: TOVX) announced awareness of unusual trading activity in its common stock on the NYSE American on October 24, 2025. The company said it has made inquiries, does not believe corrective actions are appropriate, and is not aware of any material development in its business or affairs that would explain the trading.
The company noted a prior announcement on October 13, 2025 about presenting expanded data from the VIRAGE trial of VCN-01 at a mini oral session during ESMO 2025.
Positive
- None.
Negative
- None.
News Market Reaction 111 Alerts
On the day this news was published, TOVX gained 0.88%, reflecting a mild positive market reaction. Argus tracked a peak move of +113.9% during that session. Argus tracked a trough of -23.1% from its starting point during tracking. Our momentum scanner triggered 111 alerts that day, indicating very high trading interest and price volatility. This price movement added approximately $71K to the company's valuation, bringing the market cap to $8M at that time. Trading volume was exceptionally heavy at 38.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the “NYSE”) on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and does not believe corrective actions are appropriate. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action. However, on October 13, 2025, the Company announced the presentation of expanded data from its VIRAGE trial investigating VCN-01 at a mini oral session at the European Society for Medical Oncology (ESMO 2025) Annual Congress.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
For further information, please contact:
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
What did Theriva Biologics (TOVX) say about the unusual trading on October 24, 2025?
Did Theriva (TOVX) report any material developments to explain the October 24, 2025 trading?
When did Theriva announce the VIRAGE VCN-01 presentation referenced in the October 24, 2025 notice?
Where will investors find more information about Theriva Biologics (TOVX) disclosures?
Does the October 24, 2025 statement by Theriva (TOVX) indicate any regulatory or enforcement action?
